Related Experiment Video

Updated: Jun 17, 2026

Exploring Arterial Smooth Muscle Kv7 Potassium Channel Function using Patch Clamp Electrophysiology and Pressure Myography
11:02

Exploring Arterial Smooth Muscle Kv7 Potassium Channel Function using Patch Clamp Electrophysiology and Pressure Myography

Published on: September 14, 2012

Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease

Ralf Köhler1, Brajesh P Kaistha, Heike Wulff

  • 1Institute of Medical Biology, Depatrment of Physiology, SDU, J.B. Winsløwsvej 21 3., 5000 Odense C, Denmark. rkohler@health.sdu.dk

Expert Opinion on Therapeutic Targets
|January 9, 2010
PubMed

Insights

Novel small molecules targeting Ca(2+)-activated K(+) channels (K(Ca)) show promise for treating cardiovascular diseases like hypertension and restenosis. Further research is needed to optimize these K(Ca) channel modulators for therapeutic use.

Area of Science:

  • Cardiovascular pharmacology
  • Ion channel research
  • Vascular biology

Background:

  • Cardiovascular diseases are a major global health concern.
  • Hyperpolarizing Ca(2+)-activated K(+) channels (K(Ca)) are critical regulators of vascular tone and remodeling.
  • K(Ca) channels represent promising therapeutic targets for cardiovascular pathologies.

Purpose of the Study:

  • To review recent advancements in vascular K(Ca) channel research.
  • To explore the role of K(Ca) channels in hypertension and restenosis.
  • To highlight novel small-molecule modulators and their therapeutic potential.

Main Methods:

  • Literature review focusing on the last 4-5 years.
  • Analysis of K(Ca) channel function in cardiovascular diseases.
  • Evaluation of small-molecule channel modulators for therapeutic utility.

Main Results:

  • Opening endothelial KCa3.1/KCa2.3 channels promotes vasodilation and lowers blood pressure.
  • Inhibiting smooth muscle KCa3.1 channels offers benefits in restenosis and atherosclerosis.
  • KCa3.1/KCa2.3 openers and KCa3.1 blockers present distinct therapeutic strategies.

Conclusions:

  • Pharmacological targeting of vascular K(Ca) channels offers new treatment avenues for hypertension, restenosis, and atherosclerosis.
  • Novel small-molecule modulators show potential as cardiovascular drugs.
  • Further optimization and validation are necessary for clinical application.
Abstract

More Related Videos

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique07:19

Recording of Inward Rectifying K+ Currents in Freshly Isolated Basilar Artery Smooth Muscle Cells by Patch Clamp Technique

Published on: February 7, 2025

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...